Fibrinogen concentrate vs. fresh frozen plasma for the management of coagulopathy during thoraco-abdominal aortic aneurysm surgery: a pilot randomised controlled trial

G. A. Morrison*, J. Koch, M. Royds, D. McGee, R. T.A. Chalmers, J. Anderson, A. F. Nimmo

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)


Major vascular surgery is frequently associated with significant blood loss and coagulopathy. Existing evidence suggests hypofibrinogenaemia develops earlier than other haemostatic deficiencies during major blood loss. The purpose of this study was to assess whether the use of an infusion of fibrinogen concentrate to prevent and treat hypofibrinogenaemia during surgery resulted in satisfactory haemostasis, removing or reducing the need for blood component transfusion. Twenty patients undergoing elective extent-4 thoraco-abdominal aortic aneurysm repair were randomly allocated to receive either fresh frozen plasma or fibrinogen concentrate to treat hypofibrinogenaemia during surgery. Coagulation was assessed during and after surgery by point-of-care and laboratory testing, respectively, and treatment was guided by pre-defined transfusion triggers. Despite blood losses of up to 11,800 ml in the patients who received the fibrinogen concentrate, none required fresh frozen plasma during surgery, and only two required platelet transfusions. The median (IQR [range]) allogeneic blood component administration during surgery and in the first 24 h postoperatively was 22.5 (14–28 [2–41]) units in patients allocated to fresh frozen plasma vs. 4.5 (3–11[0–17]) in patients allocated to fibrinogen concentrate (p = 0.011). All patients in both groups were assessed by the surgeon to have satisfactory haemostasis at the end of surgery. Mean (SD) postoperative fibrinogen concentrations were similar in patients allocated to fresh frozen plasma and fibrinogen concentrate (1.6 (0.3) g.l−1 vs. 1.6 (0.2) g.l−1; p = 0.36) but the mean (SD) international normalised ratio and activated partial thromboplastin time ratio were lower in patients allocated to fresh frozen plasma (1.1 (0.1) vs. 1.8 (0.3); p < 0.0001 and 1.1 (0.2) vs. 1.7 (0.5); p = 0.032, respectively). Fibrinogen concentrate may be used as an alternative to fresh frozen plasma in the treatment of coagulopathy during thoraco-abdominal aortic aneurysm repair.

Original languageEnglish
Pages (from-to)180-189
Number of pages10
Issue number2
Publication statusPublished - Feb 2019
Externally publishedYes

Bibliographical note

Funding Information:
Registered at (NCT00994045). The authors thank Dr C. Moores, Dr A. Thomson, Mrs P. Burns, Mr O. Falah and the operating department practitioners in theatre 18 at The Royal Infirmary of Edinburgh for their assistance during this study. This investigator-initiated study was partly funded by CSL Behring (King of Prussia, PA, USA) who supplied the fibrinogen concentrate used in the study and provided funding towards the costs of laboratory coagulation tests. CSL Behring had no involvement in the analysis of the data or writing of the manuscript. AN has received payment and travel funding for an overseas lecture from CSL Behring, and payments as a member of clinical advisory boards from CSL Behring and LFB Biopharmaceuticals Limited. No other competing interests.

Publisher Copyright:
© 2018 Association of Anaesthetists


  • fibrinogen concentrate
  • fresh frozen plasma
  • thoraco-abdominal aortic aneurysm surgery
  • vascular anaesthesia


Dive into the research topics of 'Fibrinogen concentrate vs. fresh frozen plasma for the management of coagulopathy during thoraco-abdominal aortic aneurysm surgery: a pilot randomised controlled trial'. Together they form a unique fingerprint.

Cite this